• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Entresto (sacubitril and valsartan)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Entresto (sacubitril and valsartan)

  • Profile

Profile

Contact Information

Contact: Novartis
Website: www.entresto.com

Currently Enrolling Trials

    Show More

    General Information

    Entresto is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker.

    Entresto is specifically indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure and for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.

    Entresto is supplied as a tablet for oral administration. The recommended dosing/administration is as follows:

    Adults:

    • The recommended starting dose is 49/51 mg orally twice-daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

    Pediatrics:

    Refer to the table below. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient. In pediatric patients less than 40 kg the use of the Oral Suspension is recommended. Recommended mg/kg doses are of the combined amount of both sacubitril and valsartan.

                                                                                      Titration Step Dose (twice daily)

      Starting Second Final
    Pediatric Patients Less than 40 kg 1.6 mg/kg 2.3 mg/kg 3.1 mg/kg
    Pediatric Patients At least 40 kg, less than 50 kg 24/26 mg 49/51 mg 72/78 mg
    Pediatric Patients At least 50 kg 49/51 mg 72/78 mg 97/103 mg

    Mechanism of Action

    Entresto is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker.  Entresto inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1) receptor via valsartan. The cardiovascular and renal effects of Entresto in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release. 

    Side Effects

    Adverse effects associated with the use of Entresto may include, but are not limited to, the following:

    • hypotension
    • hyperkalemia
    • cough
    • dizziness
    • renal failure

    Clinical Trial Results

    Dosing in clinical trials was based on the total amount of both components of Entresto, i.e., 24/26 mg, 49/51 mg and 97/103 mg were referred to as 50 mg, 100 mg, and 200 mg, respectively. The FDA approval of Entresto was based on PARADIGM-HF, a multinational, randomized, double-blind trial comparing Entresto and enalapril in 8,442 adult patients with symptomatic chronic heart failure (NYHA class II–IV) and systolic dysfunction (left ventricular ejection fraction ≤ 40%). The primary objective of PARADIGM-HF was to determine whether Entresto was superior to a RAS inhibitor (enalapril) alone in reducing the risk of the combined endpoint of cardiovascular (CV) death or hospitalization for heart failure (HF). After discontinuing their existing ACE inhibitor or ARB therapy, patients entered sequential single-blind run-in periods during which they received enalapril 10 mg twice-daily, followed by Entresto 100 mg twice-daily, increasing to 200 mg twice daily. Patients who successfully completed the sequential run-in periods were randomized to receive either Entresto 200 mg (N=4,209) twice-daily or enalapril 10 mg (N=4,233) twice-daily. The median follow-up duration was 27 months and patients were treated for up to 4.3 years. PARADIGM-HF demonstrated that Entresto was superior to enalapril in reducing the risk of the combined endpoint of cardiovascular death or hospitalization for heart failure, based on a time-to-event analysis. The treatment effect reflected a reduction in both cardiovascular death and heart failure hospitalization. Sudden death accounted for 45% of cardiovascular deaths, followed by pump failure, which accounted for 26%. Entresto also improved overall survival. This finding was driven entirely by a lower incidence of cardiovascular mortality on Entresto.

    Approval Date: 2015-07-01
    Company Name: Novartis
    Back to Listings

    Upcoming Events

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    • White House

      Trial Stakeholders Advise White House on Emergency Research Infrastructure

    • SurveywBlueBackground-360x240.png

      Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing